BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35619903)

  • 1. AQP5 Is a Novel Prognostic Biomarker in Pancreatic Adenocarcinoma.
    Chen G; Song H; Yang Z; Du T; Zheng Y; Lu Z; Zhang K; Wei D
    Front Oncol; 2022; 12():890193. PubMed ID: 35619903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High expression of RNF169 is associated with poor prognosis in pancreatic adenocarcinoma by regulating tumour immune infiltration.
    Wang J; Chen H; Deng Q; Chen Y; Wang Z; Yan Z; Wang Y; Tang H; Liang H; Jiang Y
    Front Genet; 2022; 13():1022626. PubMed ID: 36685833
    [No Abstract]   [Full Text] [Related]  

  • 3. Bioinformatics analysis identified MMP14 and COL12A1 as immune-related biomarkers associated with pancreatic adenocarcinoma prognosis.
    Li Y; Su Z; Wei B; Qin M; Liang Z
    Math Biosci Eng; 2021 Jun; 18(5):5921-5942. PubMed ID: 34517516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CHST12: a potential prognostic biomarker related to the immunotherapy response in pancreatic adenocarcinoma.
    Liu K; Li L; Han G
    Front Endocrinol (Lausanne); 2023; 14():1226547. PubMed ID: 38333724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel immune checkpoint score system for prognostic evaluation in pancreatic adenocarcinoma.
    Chen Y; Lin X; Zou X; Qian Y; Liu Y; Wang R; Wang X; Yu X; Liu C; Cheng H
    BMC Gastroenterol; 2023 Apr; 23(1):113. PubMed ID: 37024802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KRT7 Overexpression is Associated with Poor Prognosis and Immune Cell Infiltration in Patients with Pancreatic Adenocarcinoma.
    Li Y; Su Z; Wei B; Liang Z
    Int J Gen Med; 2021; 14():2677-2694. PubMed ID: 34188523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpressing PLOD Family Genes Predict Poor Prognosis in Pancreatic Cancer.
    Zhang J; Tian Y; Mo S; Fu X
    Int J Gen Med; 2022; 15():3077-3096. PubMed ID: 35330878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of therapeutic targets and prognostic biomarkers of the ephrin receptor subfamily in pancreatic adenocarcinoma.
    Zou J; Zhang K; Zhu J; Tu C; Guo J
    J Int Med Res; 2024 Jan; 52(1):3000605231218559. PubMed ID: 38180878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identify potential prognostic indicators and tumor-infiltrating immune cells in pancreatic adenocarcinoma.
    Shi T; Gao G
    Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35083488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PANX1 is a potential prognostic biomarker associated with immune infiltration in pancreatic adenocarcinoma: A pan-cancer analysis.
    Bao L; Sun K; Zhang X
    Channels (Austin); 2021 Dec; 15(1):680-696. PubMed ID: 34796785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and Validation of an Inflammatory Response-Related Gene Signature for Predicting the Prognosis of Pancreatic Adenocarcinoma.
    Deng ZL; Zhou DZ; Cao SJ; Li Q; Zhang JF; Xie H
    Inflammation; 2022 Aug; 45(4):1732-1751. PubMed ID: 35322324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transmembrane Protein 170B is a Prognostic Biomarker and Associated With Immune Infiltrates in Pancreatic Adenocarcinoma.
    Zhang Z; Shang J; Dai Z; Yao Y; Shi Y; Zhong D; Liang Y; Lai C; Yang Q; Feng T; Huang X
    Front Genet; 2022; 13():848391. PubMed ID: 35601487
    [No Abstract]   [Full Text] [Related]  

  • 13. System analysis based on the pyroptosis-related genes identifies GSDMC as a novel therapy target for pancreatic adenocarcinoma.
    Yan C; Niu Y; Li F; Zhao W; Ma L
    J Transl Med; 2022 Oct; 20(1):455. PubMed ID: 36199146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Potential Prognostic Marker PRDM1 in Pancreatic Adenocarcinoma.
    Zhou B; Zhang J; Zhu H; Wu S
    J Oncol; 2022; 2022():1934381. PubMed ID: 35607327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Values and Clinical Significance of S100 Family Member's Individualized mRNA Expression in Pancreatic Adenocarcinoma.
    Li X; Qiu N; Li Q
    Front Genet; 2021; 12():758725. PubMed ID: 34804125
    [No Abstract]   [Full Text] [Related]  

  • 16. m6A regulators are differently expressed and correlated with immune response of pancreatic adenocarcinoma.
    Zhang T; Sheng P; Jiang Y
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):2805-2822. PubMed ID: 35780396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive Analysis of Prognostic and Immune Infiltrates for E2F Transcription Factors in Human Pancreatic Adenocarcinoma.
    Liu XS; Gao Y; Liu C; Chen XQ; Zhou LM; Yang JW; Kui XY; Pei ZJ
    Front Oncol; 2020; 10():606735. PubMed ID: 33604289
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Yang Y; Ren L; Li S; Zheng X; Liu J; Li W; Fu W; Wang J; Du G
    Transl Cancer Res; 2022 Apr; 11(4):649-668. PubMed ID: 35571651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling of new markers for the diagnosis and prognosis of pancreatic cancer based on the transition from inflammation to cancer.
    Zhou Y; Huang B; Zhang Q; Yu Y; Xiao J
    Transl Cancer Res; 2024 Mar; 13(3):1425-1442. PubMed ID: 38617519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High Matrix Metalloproteinase 28 Expression is Associated with Poor Prognosis in Pancreatic Adenocarcinoma.
    Liu N; Zhong L; Ni G; Lin J; Xie L; Li T; Dan H; Chen Q
    Onco Targets Ther; 2021; 14():4391-4406. PubMed ID: 34408436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.